The Canadian Drug Expert Committee (CDEC) has recommended that intravenous golimumab (Simponi IV) be listed for use in combination with methotrexate for the treatment of adult patients with moderately to severely active rheumatoid arthritis if the following conditions are met:

1. List in a manner similar to subcutaneous golimumab

2. The overall drug plan cost of treatment with IV golimumab should not exceed the overall drug plan cost of treatment with SC golimumab

For more details, go to: http://www.cadth.ca/media/cdr/complete/SR0351_complete_Simponi_IV_Jul-21-14.pdf